Pfizer Inc. (PFE)
26.38
0.19 (0.73%)
At close: Mar 21, 2025, 3:59 PM
Pfizer Inc. Revenue Breakdown
| Quarter | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | Dec 31, 2021 | Oct 3, 2021 | Jul 4, 2021 | Apr 4, 2021 | Dec 31, 2020 | Sep 27, 2020 | Jun 28, 2020 | Mar 29, 2020 | Dec 31, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | Jun 28, 2015 | Mar 29, 2015 | Dec 31, 2014 | Sep 28, 2014 | Jun 29, 2014 | Mar 30, 2014 | Dec 31, 2013 | Sep 29, 2013 | Jun 30, 2013 | Mar 31, 2013 | Dec 31, 2012 | Sep 30, 2012 | Jul 1, 2012 | Apr 1, 2012 | Dec 31, 2011 | Oct 2, 2011 | Jul 3, 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biopharma Segment Revenue | 17.39B | 2.07B | 2.17B | 1.91B | 1.65B | 1.97B | 2.06B | 2.22B | 1.69B | 2.32B | 2.31B | 1.93B | 2.07B | 1.88B | 1.77B | 0 | 22.35B | 21.6B | 22.04B | 0 | 22.79B | 22.86B | 22.3B | 10.88B | 9.95B | 12.08B | 11.42B | 11.73B | 10.48B | 12.48B | 11.74B | 12.11B | 11.55B | 12.89B | 12.12B | 13.14B | 13.06B | 28.36B | 14.75B | 14.64B |
| Biopharma Segment Revenue Growth | +741.41% | -4.83% | +13.72% | +16.11% | -16.37% | -4.51% | -7.08% | +31.26% | -27.10% | +0.13% | +19.65% | -6.48% | +10.00% | +6.21% | n/a | -100.00% | +3.47% | -1.99% | n/a | -100.00% | -0.31% | +2.49% | +104.99% | +9.40% | -17.69% | +5.81% | -2.63% | +11.91% | -16.03% | +6.29% | -3.04% | +4.88% | -10.45% | +6.40% | -7.78% | +0.57% | -53.93% | +92.31% | +0.73% | n/a |
Revenue by Geography
| Quarter | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 | Dec 31, 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Developed Europe Revenue | 11.65B | 21.98B | 18.34B | 7.79B | 8.7B | 9.12B | 8.51B | 9.31B | 9.71B | 11.72B | 11.74B | 13.38B | 16.3B | 16.66B |
| Developed Europe Revenue Growth | -47.00% | +19.88% | +135.44% | -10.49% | -4.55% | +7.15% | -8.58% | -4.20% | -17.11% | -0.17% | -12.23% | -17.93% | -2.21% | n/a |
| Developed Rest Of World Revenue | 7.76B | 15.78B | 12.51B | 4.04B | 6.46B | 6.55B | 6.61B | 6.73B | 6.3B | 7.31B | 8.35B | 10.55B | 11.09B | 10.09B |
| Developed Rest Of World Revenue Growth | -50.81% | +26.16% | +209.86% | -37.57% | -1.31% | -0.92% | -1.74% | +6.84% | -13.89% | -12.37% | -20.92% | -4.84% | +9.91% | n/a |
| Emerging Markets Revenue | 12B | 20.1B | 20.7B | 8.37B | 12.73B | 12.65B | 11.4B | 10.42B | 11.14B | 11.5B | 11.22B | 11.97B | 13.1B | 12.01B |
| Emerging Markets Revenue Growth | -40.31% | -2.92% | +147.26% | -34.25% | +0.65% | +10.98% | +9.40% | -6.43% | -3.16% | +2.44% | -6.23% | -8.65% | +9.14% | n/a |
| United States Revenue | 27.09B | 42.47B | 29.75B | 21.71B | 23.85B | 25.33B | 26.03B | 26.37B | 21.7B | 19.07B | 20.27B | 23.09B | n/a | n/a |
| United States Revenue Growth | -36.22% | +42.79% | +37.00% | -8.97% | -5.83% | -2.68% | -1.30% | +21.49% | +13.79% | -5.92% | -12.18% | n/a | n/a | n/a |
Operating Expense Breakdown
| Quarter | Dec 31, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | Dec 31, 2021 | Oct 3, 2021 | Jul 4, 2021 | Apr 4, 2021 | Dec 31, 2020 | Sep 27, 2020 | Jun 28, 2020 | Mar 29, 2020 | Dec 31, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jul 1, 2018 | Apr 1, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | Dec 31, 2016 | Oct 2, 2016 | Jul 3, 2016 | Apr 3, 2016 | Dec 31, 2015 | Sep 27, 2015 | Jun 28, 2015 | Mar 29, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 4.27B | 3.24B | 3.69B | 3.46B | 4.48B | 3.21B | 3.43B | 3.36B | 4.64B | 3.39B | 2.91B | 2.59B | 4.1B | 2.9B | 2.93B | 2.78B | 3.76B | 3.02B | 3.03B | 2.87B | 4.24B | 3.26B | 3.51B | 3.34B | 4.01B | 3.49B | 3.54B | 3.41B | 4.55B | 3.5B | 3.42B | 3.31B | 4.42B | 3.56B | 3.47B | 3.38B | 5.05B | 3.27B | 3.39B | 3.1B |
| Selling, General, and Administrative Revenue Growth | +31.75% | -12.04% | +6.62% | -22.74% | +39.38% | -6.41% | +2.17% | -27.67% | +36.95% | +16.37% | +12.38% | -36.82% | +41.27% | -0.79% | +5.21% | -25.92% | +24.57% | -0.46% | +5.46% | -32.24% | +30.06% | -7.15% | +5.15% | -16.67% | +14.68% | -1.36% | +3.81% | -25.03% | +30.03% | +2.19% | +3.54% | -25.21% | +24.28% | +2.54% | +2.54% | -32.94% | +54.37% | -3.43% | +9.09% | n/a |
| Research and Development Revenue | 3.12B | 2.6B | 2.68B | 2.48B | 2.77B | 2.68B | 2.63B | 2.49B | 3.62B | 2.7B | 2.81B | 2.3B | 5.92B | 3.45B | 2.46B | 2.01B | 3.35B | 2.36B | 2.13B | 1.72B | 2.82B | 2.28B | 1.84B | 1.7B | 2.46B | 2.01B | 1.8B | 1.74B | 2.31B | 1.86B | 1.78B | 1.71B | 2.51B | 1.88B | 1.75B | 1.73B | 2.35B | 1.72B | 1.73B | 1.89B |
| Research and Development Revenue Growth | +20.21% | -2.91% | +7.90% | -10.57% | +3.39% | +2.02% | +5.41% | -31.01% | +34.09% | -4.23% | +22.34% | -61.10% | +71.60% | +40.18% | +22.10% | -39.95% | +42.12% | +10.69% | +23.67% | -38.91% | +23.61% | +23.94% | +8.16% | -30.69% | +22.36% | +11.74% | +3.10% | -24.58% | +24.31% | +4.44% | +4.22% | -32.01% | +33.55% | +7.61% | +0.98% | -26.28% | +36.35% | -0.69% | -8.01% | n/a |